Physician profile
Dan E Calleja
NPI 1871532366
$2,427.31
in general payments reported to CMS, 2019-2025
32 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $392 · 2021: $160 · 2022: $78.79 · 2023: $224 · 2024: $270 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $804.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $393.47 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.54 | 2019-2025 | Jardiance |
| Pfizer INC. | $284.01 | 2019-2024 | |
| Amgen INC. | $215.14 | 2019-2025 | Evenity, Prolia |
| Novo Nordisk INC | $167.13 | 2019-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $108.43 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.09 | 2020-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $74.03 | 2024-2025 | Dexcom G6 Transmitter |
| Inogen, INC. | $73.06 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Otsuka America Pharmaceutical, INC. | $63.56 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $61.84 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $60.04 | 2019-2025 | Capvaxive |
| Abbott Laboratories | $56.62 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Allergan, INC. | $52.98 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $52.29 | 2024-2025 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $38.47 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $35.97 | 2019-2020 | |
| Ibsa Pharma INC. | $33.99 | 2020 | |
| Insulet Corporation | $32.22 | 2020 | |
| Exact Sciences Corporation | $30.37 | 2024-2025 | Cologuard Collection Kit |
| Harmony Biosciences LLC | $23.95 | 2023 | Wakix |
| Bausch Health US, LLC | $20.42 | 2021 | |
| Mylan Specialty L.P. | $20.40 | 2020 | |
| Eisai INC. | $18.87 | 2020 | |
| Ferring Pharmaceuticals INC. | $18.54 | 2024 | Rebyota |
| Lundbeck LLC | $16.52 | 2024 | Rexulti |
| Abbvie INC. | $15.59 | 2020 | |
| Glaxosmithkline, LLC. | $12.85 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.94 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.86 | 2021 | |
| Esperion Therapeutics, INC. | $11.82 | 2020 | |
| Amarin Pharma, INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Calleja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.